当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
Verquvo
申请企业
MERCK SHARP AND DOHME CORP
承诺描述
A double-blind, randomized, placebo-controlled, clinical trial to evaluate PK, the efficacy and safety of vericiguat in pediatric patients >28 days to <18 years with heart failure due to left ventricular systolic dysfunction consistent with dilated cardiomyopathy.
承诺状态描述
The study has not been initiated, but it does not meet the criterion for delayed.